NextCure (NXTC) has an average rating among analysts of buy, with an average price target of $66. Price: 56.70, Change: -1.67, Percent Change: -2.86 ...
NextCure's (NXTC) average rating among analysts is a buy, with an average price target of $61. Price: 50.96, Change: -0.05, Percent Change: -0.10 ...
Price: 39.61, Change: -0.23, Percent Change: -0.57 ...
NextCure (NXTC) said Thursday that it priced its public offering of 4,077,192 common shares at $36.75 per share, for gross proceeds of about $150 million. ...
| Address | 9000 Virginia Manor Road Beltsville, Maryland 20705 |
| Phone | +1.240.399.4900 |
| Number of Employees | 44 |
| Recent SEC Filing | 01/13/2020 8-K |
| President, Chief Executive Officer & Director | Michael S. Richman |
| Chief Operating Officer | Timothy Mayer |
| Chief Financial Officer | Steven P. Cobourn |
| Chief Scientific Officer | Solomon Langermann |
| Price Open | $47.15 |
| Previous Close | $47.10 |
| 52 Week Range | $13.86 - 109.00 |
| Market Capitalization | $1.0 B |
| Shares Outstanding | 22.8 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/11/2020 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.48 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -645.81% |
| Return on Equity | -24.45% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
